Drug updated on 4/17/2024
| Dosage Form | Liquid (oral; 1.1 g/mL) |
| Drug Class | Nitrogen-binding agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For chronic management of patients with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Ravicti (glycerol phenylbutyrate) Prescribing Information. | 2021 | Horizon Therapeutics USA, Inc. Deerfield, IL |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. | 2019 | Journal of Inherited Metabolic Disease |